SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
SPRO reported Third quarter ended September 30, 2026 results. The price and volatility reaction is pending.
SPROearnings

Earnings reactions, page 3

Spero Therapeutics, Inc. (SPRO) Q3 FY2026 earnings

November 13, 2026 · SharpeIQ Research Desk

Reported results

  • Research and development expenses were $38.2 million for the third quarter of 2026.
  • Net loss was $44.3 million for the third quarter of 2026.
  • Total revenue was $0 for the third quarter of 2026.
  • General and administrative expenses were $3.7 million for the third quarter of 2026.
  • Cash and cash equivalents were $107.9 million as of September 30, 2026.

Guidance

  • Spero expects its cash and cash equivalents will be sufficient to fund operating expenses and capital expenditures into the second half of 2029.
  • Spero plans to initiate a Phase 2 study for SP001 in IgG4-RD in Q2 2027.

Price and volatility reaction

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-12 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →